BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ - Get Free Report)'s share price reached a new 52-week high during trading on Monday . The stock traded as high as $1.80 and last traded at $1.50, with a volume of 79022 shares. The stock had previously closed at $1.56.
BioRestorative Therapies Stock Down 3.8 %
The stock has a 50-day moving average of $1.64 and a 200 day moving average of $1.58. The stock has a market cap of $2.46 billion, a PE ratio of -1.46 and a beta of 102.36.
BioRestorative Therapies Company Profile
(
Get Free Report)
BioRestorative Therapies, Inc develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioRestorative Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioRestorative Therapies wasn't on the list.
While BioRestorative Therapies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
